JP2011525902A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011525902A5 JP2011525902A5 JP2011515663A JP2011515663A JP2011525902A5 JP 2011525902 A5 JP2011525902 A5 JP 2011525902A5 JP 2011515663 A JP2011515663 A JP 2011515663A JP 2011515663 A JP2011515663 A JP 2011515663A JP 2011525902 A5 JP2011525902 A5 JP 2011525902A5
- Authority
- JP
- Japan
- Prior art keywords
- pathogen
- immune response
- subject
- composition
- immunogenic composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13314008P | 2008-06-25 | 2008-06-25 | |
| US61/133,140 | 2008-06-25 | ||
| PCT/IB2009/006260 WO2009156852A1 (en) | 2008-06-25 | 2009-06-25 | Rapid responses to delayed booster immunisations |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011525902A JP2011525902A (ja) | 2011-09-29 |
| JP2011525902A5 true JP2011525902A5 (enExample) | 2012-08-09 |
| JP5712126B2 JP5712126B2 (ja) | 2015-05-07 |
Family
ID=41171092
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011515663A Expired - Fee Related JP5712126B2 (ja) | 2008-06-25 | 2009-06-25 | 遅延型追加刺激免疫処置に対する迅速な応答 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US9421251B2 (enExample) |
| EP (1) | EP2310045A1 (enExample) |
| JP (1) | JP5712126B2 (enExample) |
| CA (1) | CA2729248A1 (enExample) |
| WO (1) | WO2009156852A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2557382T3 (es) | 2010-07-06 | 2016-01-25 | Glaxosmithkline Biologicals Sa | Liposomas con lípidos que tienen un valor de pKa ventajoso para el suministro de ARN |
| EP2591114B1 (en) | 2010-07-06 | 2016-06-08 | GlaxoSmithKline Biologicals SA | Immunisation of large mammals with low doses of rna |
| ES2646669T3 (es) | 2010-07-06 | 2017-12-14 | Glaxosmithkline Biologicals Sa | Procedimientos de aumento de una respuesta inmunitaria mediante el suministro de ARN |
| LT4226941T (lt) | 2010-08-31 | 2025-01-10 | Glaxosmithkline Biologicals Sa | Pegilintos liposomos, skirtos imunogeną koduojančios rnr pristatymui |
| WO2012051211A2 (en) | 2010-10-11 | 2012-04-19 | Novartis Ag | Antigen delivery platforms |
| TWI815599B (zh) | 2011-04-22 | 2023-09-11 | 美商惠氏有限責任公司 | 與難養芽胞梭菌（Ｃｌｏｓｔｒｉｄｉｕｍ ｄｉｆｆｉｃｉｌｅ）之突變毒素有關之組成物及彼之方法 |
| CA2841047A1 (en) | 2011-07-06 | 2013-01-10 | Novartis Ag | Immunogenic compositions and uses thereof |
| EP2729165B1 (en) | 2011-07-06 | 2017-11-08 | GlaxoSmithKline Biologicals SA | Immunogenic combination compositions and uses thereof |
| BR122016023101B1 (pt) | 2012-10-21 | 2022-03-22 | Pfizer Inc | Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile |
| WO2021255690A2 (en) | 2020-06-19 | 2021-12-23 | Pfizer Inc. | Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9923176D0 (en) | 1999-09-30 | 1999-12-01 | Smithkline Beecham Biolog | Novel composition |
| CA2439111A1 (en) | 2001-04-05 | 2002-10-17 | Chiron Corporation | Mucosal boosting following parenteral priming |
| US8080255B2 (en) | 2003-07-11 | 2011-12-20 | Novavax Inc. | Functional influenza virus like particles (VLPs) |
| TWI365074B (en) | 2004-10-07 | 2012-06-01 | Wyeth Corp | Multivalent avian influenza vaccines |
| CN101072585A (zh) * | 2004-11-01 | 2007-11-14 | 诺华疫苗和诊断公司 | 产生免疫应答的组合方法 |
| AR054020A1 (es) | 2005-03-23 | 2007-05-30 | Glaxosmithkline Biolog Sa | Nuevo uso |
| AU2006310338A1 (en) | 2005-11-04 | 2007-05-10 | Novartis Vaccines And Diagnostics Srl | Adminstration routes for priming/boosting with influenza vaccines |
| NZ594482A (en) | 2005-11-04 | 2012-11-30 | Novartis Vaccines & Diagnostic | Influenza vaccines with reduced amount of oil-in-water emulsion as adjuvant |
| WO2007130330A2 (en) | 2006-05-01 | 2007-11-15 | Technovax, Inc. | Polyvalent influenza virus-like particle (vlp) compositions |
| US20080014217A1 (en) | 2006-07-17 | 2008-01-17 | Emmanuel Jules Hanon | Influenza vaccine |
| MX2009000660A (es) | 2006-07-17 | 2009-04-08 | Glaxosmithkline Biolog Sa | Vacuna de influenza. |
| GB0810305D0 (en) | 2008-06-05 | 2008-07-09 | Novartis Ag | Influenza vaccination |
-
2009
- 2009-06-25 EP EP09769663A patent/EP2310045A1/en not_active Withdrawn
- 2009-06-25 JP JP2011515663A patent/JP5712126B2/ja not_active Expired - Fee Related
- 2009-06-25 US US12/999,848 patent/US9421251B2/en not_active Expired - Fee Related
- 2009-06-25 WO PCT/IB2009/006260 patent/WO2009156852A1/en not_active Ceased
- 2009-06-25 CA CA2729248A patent/CA2729248A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011525902A5 (enExample) | ||
| Kim et al. | Influenza vaccines: Past, present, and future | |
| JP6308500B2 (ja) | 強化された免疫賦活化剤 | |
| Jabbal-Gill | Nasal vaccine innovation | |
| Alving et al. | Adjuvants for human vaccines | |
| Tan et al. | Outer membrane vesicles: current status and future direction of these novel vaccine adjuvants | |
| Levitz et al. | Beyond empiricism: informing vaccine development through innate immunity research | |
| Mori et al. | The vaccine adjuvant alum inhibits IL‐12 by promoting PI 3 kinase signaling while chitosan does not inhibit IL‐12 and enhances T h1 and T h17 responses | |
| Skene et al. | Saponin-adjuvanted particulate vaccines for clinical use | |
| Yusuf et al. | Current prospects and future challenges for nasal vaccine delivery | |
| Riese et al. | Intranasal formulations: promising strategy to deliver vaccines | |
| Tetsutani et al. | Adjuvants in influenza vaccines | |
| de Haan et al. | Bacterium-like particles supplemented with inactivated influenza antigen induce cross-protective influenza-specific antibody responses through intranasal administration | |
| CN109364244B (zh) | 黏膜佐剂和递送系统 | |
| Dehghan et al. | Rabbit nasal immunization against influenza by dry-powder form of chitosan nanospheres encapsulated with influenza whole virus and adjuvants | |
| JP2003523310A (ja) | 新規インフルエンザウイルスワクチン組成物 | |
| TW200722101A (en) | Novel composition | |
| Cheong et al. | Epigallocatechin-3-gallate as a novel vaccine adjuvant | |
| Jones et al. | Protollin™: a novel adjuvant for intranasal vaccines | |
| Chua et al. | Opinion: making inactivated and subunit-based vaccines work | |
| JP2015529677A5 (enExample) | ||
| de Veer et al. | New developments in vaccine research—unveiling the secret of vaccine adjuvants | |
| Suresh et al. | Evaluation of mucosal adjuvants to chitosan-nanoparticle-based oral subunit vaccine for controlling salmonellosis in broilers | |
| Kavian et al. | Vaccine adjuvants as stand-alone immunoprophylaxis in strategies for 100-day rapid responses to future pandemics | |
| Glenn et al. | Safety and immunogenicity of an influenza vaccine A/H5N1 (A/Vietnam/1194/2004) when coadministered with a heat-labile enterotoxin (LT) adjuvant patch |